Key Segmentation:
By Component
-
Software
-
Services
By Deployment Mode
-
Cloud-Based
-
On-Premises
-
Hybrid
-
Software-as-a-Service (SaaS)
By Technology
-
Artificial Intelligence (AI)
-
Machine Learning (ML)
-
Natural Language Processing (NLP)
-
Robotic Process Automation (RPA)
-
Others
By Application
-
Oncology Trials
-
Rare Disease Trials
-
Cardiovascular Trials
-
Neurology Trials
-
Infectious Disease Trials
-
General Clinical Studies
-
Others
By End User
-
Pharmaceutical & Biotechnology Companies
-
Contract Research Organizations (CROs)
-
Hospitals & Clinics
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The AI-powered clinical trial recruitment market was valued at USD 1.92 billion in 2025.
The AI-powered clinical trial recruitment market is expected to grow at a CAGR of 18.62% from 2026 to 2035.
North America dominated the AI-powered clinical trial recruitment market in 2025 due to strong pharma presence, advanced healthcare infrastructure, and AI adoption.
The Oncology Trials segment dominated the market in 2025 due to high cancer burden, complex trials, and strong pharmaceutical R&D investment.
Major growth factors include demand for faster enrollment, AI driven patient matching, decentralized trials, machine learning integration, rising R&D investments, reduced dropout rates, and improved site selection efficiency globally.